XRCC6 and prostate cancer: Overall, these findings suggest that ivermectin could block NHEJ repair by targeting Ku70/Ku80 and HR repair by downregulating the expression of BRCA1 and Rad51, thereby triggering synthetic lethality in AR-positive prostate cancer cells.